1) Shinoda Y, Sawada R, Yoshikawa F, et al. Factors related to the quality of life in patients with bone metastases. Clin Exp Metastasis 2019;36(5):441-8.
2) Lawrie I and Berman R. Metastatic spinal cord compression:an oncological emergency. Eur J of Cancer Care 2009;18(5):437.
3) がんの統計編集委員会(編).がんの統計 2021年版.東京:公益財団法人がん研究振興財団;2021.p.94-8.
4) 山口さやか,中山ロバート.骨転移診療における骨転移キャンサーボードの意義.別冊整形外科.2021;79:112-7.
5) 河野博隆.がんとロコモティブシンドローム.髙木辰哉(編).脊椎転移パーフェクト診療-がんロコモを防ぐために.東京:南江堂;2020:p.2-6.
6) Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid:subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7(12):1823-9.
7) Cetin K, Christiansen CF, Jacobsen JB, et al. Bone metastasis, skeletal-related events, and mortality in lung cancerpatients:a Danish population-based cohort study. Lung Cancer 2014;86(2):247-54.
8) Yong C, Onukwugha E, Mullins CD. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol 2014;26(3):274-83.
9) 大島和也.脊椎転移のトータルケア.脊椎転移パーフェクト診療.東京:南江堂;2020:p.124-31.
10) Nakata E, Sugihara S, Sugawara Y, et al. Multidisciplinary treatment system for bone metastases for early diagnosis, treatment and prevention of malignant spinal cord compression. Oncology Lett 2020;19(4):3137-44.
11) Tateiwa D, Oshima K, Nakai T, et al. Clinical outcomes and significant factors in the survival rate after decompression surgery for patients who were non-ambulatory due to spinal metastases. J Orthop Sci 2019;24(2):347-52.
12) Takagi T, Katagiri H, Kim Y, et al. Skeletal metastasis of unknown primary origin at the initial visit:a retrospective analysis of 286 cases. PLoS One 2015;10(6):e0129428.
13) 日本臨床腫瘍学会(編).原発不明がん診療ガイドライン改訂第2版.東京:南江堂;2018.p.14-30.
14) Kato S, Hozumi T, Yamakawa K, et al. META:an MRI-based scoring system differentiating metastatic from osteoporotic vertebral fractures. Spine J 2015;15(7):1563-70.